| Identification | Back Directory | [Name]
(R)-N-Acetyl-6-(4-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone | [CAS]
220246-81-1 | [Synonyms]
OR-1896
(R)-N-Acetyl-6-(4-aminophenyl)-4,5-dihydro-5-methyl-3(2H)-pyridazinone
(R)-N-[4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]-acetamide | [Molecular Formula]
C13H15N3O2 | [MOL File]
220246-81-1.mol | [Molecular Weight]
245.28 |
| Chemical Properties | Back Directory | [Appearance]
Pale Yellow Solid | [Melting point ]
224-226°C | [density ]
1.27±0.1 g/cm3(Predicted) | [storage temp. ]
-20°C Freezer | [solubility ]
Acetone (Slightly), DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
13.67±0.60(Predicted) | [color ]
Pale Yellow to Light Yellow | [CAS DataBase Reference]
220246-81-1 |
| Hazard Information | Back Directory | [Chemical Properties]
Pale Yellow Solid | [Uses]
A metabolite of Levosimendan (L378000). | [Definition]
ChEBI: OR-1896 is an anilide and a member of acetamides. | [in vivo]
During the metabolism of Levosimendan approximately 5% of the drug is converted to the metabolite OR-1855 in the large intestine, and then acetylated in the liver to form the active metabolite OR-1896. Binding to plasma proteins is 98% for Levosimendan but only 40% for OR-1896. Unlike Levosimendan, which has an elimination half-life of 1-1.5 h, the half-life of OR-1896 is about 75 to 80 h allowing cardiovascular effects to persist up to 7 to 9 days after discontinuation of a 24-hour infusion of levosimendan. The pharmacokinetic of the parent drug is unaltered in subjects with severe renal impairment or with moderate hepatic impairment, whereas the elimination of its metabolites (OR-1896) can be prolonged[1]. | [IC 50]
PDE3/PDE Ⅲ; K+ Channel; Drug Metabolite | [storage]
Store at -20°C |
|
| Company Name: |
|
| Tel: |
821-50328103-801 18930552037 |
| Website: |
https://www.chemicalbook.com/ShowSupplierProductsList13285/0.htm |
| Company Name: |
Energy Chemical
|
| Tel: |
021-58432009 400-005-6266 |
| Website: |
http://www.energy-chemical.com |
|